Abstract 158P
Background
C-reactive protein/albumin (CRP/Alb) ratio has been identified to be associated with prognosis in pancreatic cancer. However, the role of it in biliary tract cancers has not been examined. The aim of this study is to assess the role of CRP/Alb in curatively resected extrahepatic bile duct cancers (EBDC).
Methods
We retrospectively analyzed 235 patients who underwent curative resection because of EBDC in Seoul National University Bundang Hospital between March 2005 and February 2018. The laboratory data including CRP and albumin levels were obtained by blood tests prior to surgery. The correlations among the preoperative CRP/Alb ratio, clinicopathological factors, and patient outcomes were investigated.
Results
Men were 143 (60.8%) and mean age was 68 years (range 41–85 years). EBDC perihilar bile duct cancer (n = 61) and distal bile duct cancer (n = 174). Median follow-up was 22 months and median recurrence free survival 17 months, respectively. The optimal prognostic cut-off point of the CRP/Alb ratio for tumor recurrence was 0.18. Multivariate logistic regression analysis for overall survival showed age older than 65 (HR 1.937; 95% CI 1.275–2.944; p = 0.002), advanced staging (Reference stage I, stage II - HR 1.963; 95% CI 1.261–3.056; p = 0.004, stage III - HR 2.158; 95% CI 1.155–4.031; p = 0.016), Increased CA 19-9 (HR 1.735; 95% CI 1.069–2.816; p = 0.026), and CRP/Alb ratio ³ 0.18 (HR 1.638; 95% CI 1.102–2.434; p = 0.015). Multivariate logistic regression analysis for recurrence free survival showed advanced staging (Reference stage I, stage II - HR 1.750; 95% CI 1.127–2.717; p = 0.013), venous invasion (HR 1.742; 95% CI 1.097–2.767; p = 0.019), perineural invasion (HR 2.427; 95% CI 1.114–5.287; p = 0.026), and CRP/Alb ratio ³ 0.18 (HR 1.702; 95% CI 1.144–2.531; p = 0.009).
Conclusions
Preoperative CRP/Alb ratio is significantly associated with recurrence and overall in patients with resected EBDC. Further studies are necessary to assess the role of preoperative CRP/Alb ratio in EBDC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Seoul National University Bundang Hospital.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
221P - Comparative analysis of first-line immune checkpoint inhibitor versus carboplatin-based chemotherapy for cisplatin-ineligible metastatic urothelial carcinoma: A multicenter, retrospective real-world evidence
Presenter: Hsiang‐Lan Lai
Session: Poster display session
Resources:
Abstract
222P - Does tumor grade really improve the prognostic ability of the staging system for men with penile cancer: A SEER database analysis
Presenter: Ravi Kanodia
Session: Poster display session
Resources:
Abstract
223TiP - EV-301: A phase III trial in progress evaluating enfortumab vedotin versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma
Presenter: Daniel Petrylak
Session: Poster display session
Resources:
Abstract
230P - Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort
Presenter: Lingying Wu
Session: Poster display session
Resources:
Abstract
231P - Cost-effectiveness of olaparib vs routine surveillance in the maintenance setting for patients with BRCA-mutated advanced ovarian cancer after response to first-line platinum-based chemotherapy in Singapore
Presenter: David SP Tan
Session: Poster display session
Resources:
Abstract
233P - Incorporation of correlative studies in ovarian cancers in the era of precision medicine: Assessment of accountability and utility
Presenter: Nadia Hitchen
Session: Poster display session
Resources:
Abstract
234P - Implementation of mainstream BRCA testing in epithelial ovarian cancer in a tertiary centre
Presenter: Edbert Wong
Session: Poster display session
Resources:
Abstract
235P - The efficacy of radiation therapy in ovarian carcinoma: A propensity score analysis of a population-based study
Presenter: Jian-Guo Zhou
Session: Poster display session
Resources:
Abstract
236P - Front-line maintenance therapy for platinum-sensitive ovarian cancer: What’s next PARP inhibitors?
Presenter: Han Gong
Session: Poster display session
Resources:
Abstract
237P - PARP inhibitor in platinum resistant ovarian cancer: Single center real world experience
Presenter: Saphalta Baghmar
Session: Poster display session
Resources:
Abstract